PharmAthene (PIP)
PharmAthene Profit Margin: -43.58%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
PIP Profit Margin Rankings
| Overall | 8th percentile | 4042 of 4397 |
| Sector | 32nd percentile | 317 of 470 in Healthcare |
| Industry | 59th percentile | 53 of 132 in Biotechnology |
PIP Profit Margin Range, Past 5 Years
| Minimum | -298.8% | Jun 2007 |
| Maximum | 12.01% | Dec 2011 |
| Average | -105.7% |
About Profit Margin
Profit margin represents the percentage of revenue that a company keeps as profit after accounting for fixed and variable costs. It is calculated by dividing net income by revenue. The profit margin is mainly used for internal comparisons, because acceptable profit margins vary between industries. In general, narrow profit margins indicate increased volatility. For companies with significant fixed costs, wide profit margins reduce the risk that a decline in sales will cause a net profit loss.
Displayed as a percentage, profit margin can be thought as the amount of profit that a company keeps per dollar of revenue. For example, if a company has a profit margin of 43%, the company keeps $.43 of each dollar of revenue.
Learn More
You may also be interested in these PIP related companies
PIP News
Listen to $PIP Q1 2012 earnings call - live at 04:30 PM, ondemand after - http://stks.co/3jHg
about 23 days ago by earningscast
about 23 days ago by earningscast
PharmAthene To Host First Quarter 2012 Conference Call And Webcast On Tuesday, May 8, 2012
May 02, 9:42AM PR Newswire
May 02, 9:42AM PR Newswire
$PIP shares surging; announces update on SparVax, to begin added Phase II trial, sees efficacy in humans at over 90% protection
about 49 days ago by Street_Insider
about 49 days ago by Street_Insider
PharmAthene (PIP) to Begin Added Phase II Trial on SparVax, Sees Efficacy at Over 90% Protection
Apr 12, 2:18PM Street Insider
Apr 12, 2:18PM Street Insider
PharmAthene Presents Update on SparVax™ rPA Anthrax Vaccine Program at the 2012 World Vaccine Congress
Apr 12, 2:15PM PR Newswire
Apr 12, 2:15PM PR Newswire
PharmAthene Secures $7.5M Credit Facility From GE Capital, Healthcare Financial Services
Apr 03, 9:01AM Benzinga
Apr 03, 9:01AM Benzinga
PharmAthene Secures $7.5 Million Credit Facility From GE Capital, Healthcare Financial Services
Apr 03, 9:00AM PR Newswire
Apr 03, 9:00AM PR Newswire
$PIP head fake, clean the shorts, begin the long journey to the top.
about 61 days ago by Pointman3d
about 61 days ago by Pointman3d
Advanced Cell Technology and PharmAthene Poised to Benefit From Positive Legislation
Mar 28, 8:20AM Marketwire
Mar 28, 8:20AM Marketwire
Listen to $PIP Q4 2011 earnings call - live at 04:15 PM, ondemand after - http://stks.co/2k8C
about 84 days ago by earningscast
about 84 days ago by earningscast
PharmAthene to Host Year-End 2011 Earnings Conference Call and Webcast on Thursday, March 8, 2012
Mar 06, 11:13AM PR Newswire
Mar 06, 11:13AM PR Newswire
PharmAthene to Present at the 24th Annual ROTH Conference on Monday, March 12, 2012
Mar 05, 3:23PM PR Newswire
Mar 05, 3:23PM PR Newswire
PharmAthene to Present at the Leerink Swann 2012 Global Healthcare Conference on February 15, 2012
Feb 08, 10:38AM PR Newswire
Feb 08, 10:38AM PR Newswire
PharmAthene to Present at the Noble Financial Eighth Annual Equity Conference on Tuesday, January 17, 2012
Jan 11, 2:19PM PR Newswire
Jan 11, 2:19PM PR Newswire
Pharmathene Announces Publication of Phase I Study Results for Anthrax Anti-toxin Valortim®
Dec 06, 12:39PM PR Newswire
Dec 06, 12:39PM PR Newswire
PharmAthene to Present at the Piper Jaffray 23rd Annual Healthcare Conference on November 30, 2011
Nov 28, 10:10AM PR Newswire
Nov 28, 10:10AM PR Newswire
PharmAthene to Present at the 2011 Chemical and Biological Defense Science and Technology Conference
Nov 16, 11:37AM PR Newswire
Nov 16, 11:37AM PR Newswire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| PIP | 1.21 | -0.05 | -3.97% | 60.93M |
| PIO | 16.06 | -0.03 | -0.19% | |
| PIKE | 7.22 | -0.17 | -2.30% | 256.80M |
| PII | 75.98 | -1.06 | -1.38% | 5.276B |
| PID | 13.94 | +0.03 | +0.22% | |
| PICO | 22.16 | +0.22 | +1.00% | 498.04M |
| PIC | 15.36 | -0.20 | -1.29% | |
| PIA | 9.20 | +0.02 | +0.22% | |
| PHYS | 13.31 | -0.02 | -0.15% | |
| PHX | 25.49 | +0.07 | +0.28% | 209.97M |
